IFNG and myeloid sarcoma: EP and DMF share a number of MS-relevant anti-inflammatory effects, as they suppress the release of T cell effector cytokines (IFN-γ and IL 17), reduce iNOS expression in LPS stimulated microglia, leading to NF-kB inhibition [174].